chronic hepatitis C
Conditions
Interventions
Case series:Yimitasvir100mg+Rosuvastatin10mg
Sponsors
the First Hospital of Jilin University
Eligibility
Sex/Gender
Male
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1) Subjects must be sign a written informed consent form voluntarily and fully understand the study content, process and possible adverse reactions; 2) Subjects is able to complete the study in compliance with the protocol; 3) Subjects (including partners) are willing to voluntarily take effective contraceptive measures from screening until to the last study drug administration; 4) Healthy male subjects between 18 and 45 years of age, inclusive; 5) Body weight should be=50 kg; Body Mass Index (BMI) is between 19 and 25 kg/m2, inclusive; 6) Physical examination and vital signs without clinically significant abnormalities.
Exclusion criteria
Exclusion criteria: 1) Smokers, who smoke more than 5 cigarettes/day within 3 months before the study; 2) Drink frequently, namely alcohol consumption are 14 units per week (1 unit = 285 mL of beer, or 25 mL of strong wine, or 100 mL of grape wine); 3) Donated blood or massive blood loss within 3 months before screening (>450 mL); 4) Have any disease that increases the risk of bleeding, such as acute gastritis or stomach and duodenal ulcers; 5) Have take any drug that changes liver enzyme activity within 1 month before taking the study drug; 6) Have taken any prescription drug, over-the-counter drug, vitamin product or herbal medicine within 14 days prior to screening; 7) Have participated in any clinical trial or taken any study drug within 3 months before dosing; 8) Viral hepatitis(including CHB and CHC)and positive test result of anti-HIV Ab or syphilis; 9) Have taken any alcoholic products within 24 hours prior to taking the study drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety;pharmacokinetics; | — |
Countries
China
Contacts
Public ContactRowling luo
Sunshine lake pharma co.Ltd
Outcome results
None listed